There is a number of drugs demonstrating specific activity towards hereditary cancers. For
example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the …

Background HER2-positive breast cancers are rare amongst BRCA mutation carriers. No
data exist regarding clinicopathological characteristics and prognosis of this subgroup of …

Simple Summary The importance of identifying and targeting in treating familial breast
cancers is becoming increasingly recognized, in particular with increased availability of …

The aim of this study is to delineate more clearly the prevalence of HER2+ breast cancer in
women with germline BRCA1/2 mutations. For this purpose, we analysed primary mutation …

Objective The link between BRCA1 and homologous recombination deficiency (HRD) in
cancer has gained importance with the emergence of new targeted cancer treatments, while …

At least 10% of the BRCA1/2 tests identify variants of uncertain significance (VUS) while the
distinction between pathogenic variants (PV) and benign variants (BV) remains particularly …

Deficiency in the breast cancer type 1 (BRCA1) gene expression predisposes to triple-
negative breast cancer (TNBC) and ovarian cancer (OC). We previously identified by …

At least 10% of the BRCA1/2 tests identify variants of uncertain significance (VUS) while the
distinction between pathogenic variants (PV) and benign variants (BV) remains particularly …

Background: Breast cancer is one of the most common cancers among Iranian women
whose relationship with mutation status in BRCA1 is previously approved. Therefore …

O câncer de mama e de ovário são atualmente definidos de acordo com as principais vias
envolvidas na tumorigênese. Nos cânceres de mama/ovário hereditários (HBOC), os …